RTSN NASDAQ
Retension Pharmaceuticals Inc.
1W: -10.1%
YTD: +33.5%
$13.35
-0.89 (-6.25%)
Credit Risk of going bust: not rated Bonds: none of note held by US funds details ▾
Not rated: no recent balance sheet.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$53.4M
52W Range9.66-18.64
Volume47,165
Avg Volume199,795
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOEric L. Keller
Employees12
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2026-10-09
Websiteretensionpharmaceuticals.com
1104 West Broad Street 1029
Falls Church, VA 22046
US
Falls Church, VA 22046
US
About Retension Pharmaceuticals Inc.
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Keller Eric L. | A-Award | 40,884 | $15.50 | 2026-10-22 |
| B Group, Inc. | 0 | — | 2026-10-13 |